LitCovid-sentences  

PMC:7204657 / 68-2125 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T3 0-12 Sentence denotes Dear Editor,
T4 13-184 Sentence denotes Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19.
T5 185-361 Sentence denotes Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown.
T6 362-480 Sentence denotes Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis.
T7 481-689 Sentence denotes Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients.
T8 690-802 Sentence denotes Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2].
T9 803-964 Sentence denotes The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2].
T10 965-1094 Sentence denotes The human host receptor of SARS-CoV-2 is angiotensin-converting enzyme 2 (ACE2), which is highly expressed in the intestines [3].
T11 1095-1247 Sentence denotes Intestinal viral replication is likely considering the ACE2 expression, gastrointestinal symptoms and presence of SARS-CoV-2 RNA in fecal samples [4,5].
T12 1248-1355 Sentence denotes Some gastrointestinal symptoms, such as abdominal pain, are associated with increased disease severity [5].
T13 1356-1530 Sentence denotes Furthermore, critically ill COVID-19 patients may have altered hemodynamics, potentially leading to intestinal hypoperfusion that can compromise intestinal mucosal integrity.
T14 1531-1759 Sentence denotes More studies are required to evaluate whether these variables influence the risk of intestinal perforation with tocilizumab in critical COVID-19 cases; however, clinicians should be aware of the potential for this adverse event.
T15 1760-1982 Sentence denotes Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevation and may initially go unnoticed in sedated and ventilated patients.
T16 1984-1996 Sentence denotes Declarations
T17 1997-2005 Sentence denotes Funding:
T18 2006-2010 Sentence denotes None
T19 2011-2031 Sentence denotes Competing Interests:
T20 2032-2036 Sentence denotes None
T21 2037-2057 Sentence denotes Ethical Approval: NA